Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biopharma company Crucell has signed an exclusive, commercial licensing agreement with US-based Talecris Biotherapeutics for an undisclosed and specific protein to be produced using the PER.C6 cell line.
Subscribe to our email newsletter
Crucell will receive an upfront payment of $2.5 million following the execution of the agreement and will be eligible for milestone payments of approximately $30 million across multiple indications. Further financial details of the agreement were not disclosed.
Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6 technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions, the company said.